Submit Deal

Submit Deal

Announced

4 Dec 2023

Completed

29 Jan 2024

Oxford Biomedica completed the acquisition of ABL Europe from Institut Mérieux for €15m.

Synopsis

Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, completed the acquisition of ABL Europe, a cell and gene therapy company, from Institut Mérieux, a microbiology company, for €15m.

Principals

target

Abl Europe

bidder

Oxford Biomedica

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers (26)

Service Providers

Sort

Alexander Goodman

LawyerAssociate at Covington & Burling

Sibel Yilmaz

LawyerPartner at Covington & Burling

Davide Salvi

PR ConsultantConsilium Strategic Communications

Stuart Paynter

ManagerCFO at OXFORD BIOMEDICA

Frank Mathias

ManagerCEO at OXFORD BIOMEDICA

Oliver Hodgkiss

LawyerAssociate at Covington & Burling

Rebecca Wright

LawyerAssociate at Covington & Burling

Ben Land-Maycock

LawyerSpecial Counsel at Covington & Burling

Guy Dingley

LawyerPartner at Covington & Burling

Matthew Neal

PR ConsultantPartner at Consilium Strategic Communications

Sophia Bolhassan

ManagerHead of Investor Relations at OXFORD BIOMEDICA

Mary-Jane Elliott

PR ConsultantManaging Partner at Consilium Strategic Communications

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.